- Home
- VCEL vs ALVO Comparison
VCEL vs ALVO Comparison
Compare VCEL & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCEL | ALVO |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | VCEL | ALVO |
|---|---|---|
| Price | $35.06 | $3.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $57.75 | $8.00 |
| AVG Volume (30 Days) | ★ 702.1K | 522.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.10 | $12.28 |
| Revenue Next Year | $17.95 | $21.29 |
| P/E Ratio | $110.64 | ★ $18.20 |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $3.03 |
| 52 Week High | $45.97 | $11.85 |
Technical Indicators
Market Signals| Indicator | VCEL | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 49.60 |
| Support Level | $34.26 | $3.03 |
| Resistance Level | $38.48 | $3.93 |
| Average True Range (ATR) | 1.37 | 0.21 |
| MACD | 0.46 | 0.06 |
| Stochastic Oscillator | 94.67 | 67.46 |
Price Performance
Historical ComparisonAbout VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.